Kymera Therapeutics, Inc.
KYMR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001815442
In the last 90 days, Kymera Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 276 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Kymera Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 127
- +6 vs. Q4 2022
- Shares held
- 56.9M
- +725.6K (+1.3%) vs. Q4 2022
- Total value
- $1.68B
- +$282.3M (+20.1%) vs. Q4 2022
- New holders
- 16
- 46 more added
- Sold out
- 10
- 41 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYMR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 276 | $11.1B |
| Q1 2026 | 256 | $8.01B |
| Q4 2025 | 255 | $6.99B |
| Q3 2025 | 210 | $4.58B |
| Q2 2025 | 210 | $3.44B |
| Q1 2025 | 174 | $2.00B |
| Q4 2024 | 181 | $2.89B |
| Q3 2024 | 176 | $3.27B |
| Q2 2024 | 157 | $2.01B |
| Q1 2024 | 164 | $2.70B |
| Q4 2023 | 137 | $1.54B |
| Q3 2023 | 122 | $797.2M |
| Q2 2023 | 129 | $1.34B |
| Q1 2023 | 127 | $1.68B |
| Q4 2022 | 121 | $1.40B |
| Q3 2022 | 128 | $1.15B |
| Q2 2022 | 101 | $973.6M |
| Q1 2022 | 126 | $1.93B |
| Q4 2021 | 128 | $2.76B |
| Q3 2021 | 115 | $2.04B |
| Q2 2021 | 110 | $1.29B |
| Q1 2021 | 97 | $887.2M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Kymera Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 326,322 | $9.67M | 0.00% | +88,520+37.2% | Added |
| Northern Trust Corp | 336,827 | $9.98M | 0.00% | −4,614−1.4% | Reduced |
| Massachusetts Financial Services Co | 339,147 | $10.0M | 0.00% | +339,147 | New |
| Barclays PLC | 359,928 | $10.7M | 0.01% | −30,722−7.9% | Reduced |
| Candriam Luxembourg S.C.A. | 511,476 | $13.9M | 0.10% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 566,966 | $16.8M | 0.00% | +15,443+2.8% | Added |
| Aquilo Capital Management, LLC | 601,325 | $17.8M | 10.44% | −28,086−4.5% | Reduced |
| Deer Management Co. LLC | 615,895 | $18.2M | 1.67% | 00.0% | Unchanged |
| FMR LLC | 667,351 | $19.8M | 0.00% | −178,695−21.1% | Reduced |
| Dimensional Fund Advisors LP | 739,991 | $21.9M | 0.01% | +426,831+136.3% | Added |
| Geode Capital Management, LLC | 780,829 | $23.1M | 0.00% | +33,758+4.5% | Added |
| EcoR1 Capital, LLC | 796,093 | $23.6M | 0.76% | 00.0% | Unchanged |
| Bank of New York Mellon Corp | 965,967 | $28.6M | 0.01% | −23,999−2.4% | Reduced |
| Wasatch Advisors Inc | 1,037,414 | $30.7M | 0.19% | +205,193+24.7% | Added |
| Rock Springs Capital Management LP | 1,228,379 | $36.4M | 0.87% | +6000.0% | Added |
| Artal Group S.A. | 1,805,346 | $53.5M | 3.18% | −194,654−9.7% | Reduced |
| T. Rowe Price Investment Management, Inc. | 1,968,175 | $58.3M | 0.04% | +12,198+0.6% | Added |
| Redmile Group, LLC | 2,410,769 | $71.4M | 3.10% | −263,068−9.8% | Reduced |
| State Street Corp | 2,726,825 | $80.8M | 0.00% | −119,396−4.2% | Reduced |
| Baker Bros. Advisors LP | 2,879,825 | $85.3M | 0.46% | 00.0% | Unchanged |
| BlackRock Inc. | 3,330,190 | $98.7M | 0.00% | −4,711−0.1% | Reduced |
| Vanguard Group Inc | 3,733,925 | $110.6M | 0.00% | +73,618+2.0% | Added |
| Avoro Capital Advisors LLC | 3,855,000 | $114.2M | 1.69% | +5,000+0.1% | Added |
| Wellington Management Group LLP | 4,291,018 | $127.1M | 0.03% | −300,071−6.5% | Reduced |
| Price T Rowe Associates Inc | 4,666,681 | $138.3M | 0.02% | +287,522+6.6% | Added |
| BVF Inc | 4,739,004 | $140.4M | 5.13% | +46,400+1.0% | Added |
| Atlas Venture Life Science Advisors, LLC | 5,858,262 | $173.6M | 23.50% | −126,474−2.1% | Reduced |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −99,776−100.0% | Sold out |
| Artia Global Partners LP | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −21,878−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −17,400−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −13,301−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −10,423−100.0% | Sold out |
| Independent Financial Group, LLC | 0 | $0 | 0.00% | −8,182−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −7,775−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −12−100.0% | Sold out |